Irbesartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C25H28N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J0E2756Z7N, chemically known as 1,3-diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)- but generally known as irbesartan, which bears US NIH Compound Identifier 3749. European Medicines Agency schedules Irbesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08293MIG. The term IRBESARTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules irbesartan in its Anatomical Therapeutic Chemical (ATC) Classification. IRBESARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule irbesartan under HS 29332990 and SITC 51573. As of Q4 2014, IRBESARTAN remains the US FDA Preferred Term for this commodity. Irbesartan bears US NLM identifiers UMLS ID C0595301 and NCI Concept Code C29130. SMILES: O=C1N(C(=NC21CCCC2)CCCC)Cc1ccc(cc1)c1c(cccc1)c1n[nH]nn1.